Search

Your search keyword '"Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA)"' showing total 832 results

Search Constraints

Start Over You searched for: Author "Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA)" Remove constraint Author: "Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA)"
832 results on '"Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA)"'

Search Results

2. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

3. Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib

4. Inhibition of effector antigen-specific T cells by intradermal administration of heme oxygenase-1 inducers

5. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

6. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

7. Z oonotic tuberculosis in humans assessed by next-generation sequencing: an 18-month nationwide study in Lebanon

8. Model Affitin and PEG modifications onto siRNA lipid nanocapsules: cell uptake and in vivo biodistribution improvements

9. Transfer RNA Maturation Defects Lead to Inhibition of ribosomal RNA Processing via Synthesis of pppGpp

10. Single-Unit versus Double-Unit Umbilical Cord Blood Transplantation in Children and Young Adults with Residual Leukemic Disease

11. Sequential mutational evaluation of CALR ‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression

12. In vivo evidence for transintestinal cholesterol efflux in patients with complete common bile duct obstruction

13. BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice

14. Microdeletion on chromosome 8p23.1 in a familial form of severe Buruli ulcer

15. Loss of vascular expression of nucleoside triphosphate diphosphohydrolase-1/CD39 in hypertension

16. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

17. Pulmonary hemosiderosis in children with Down syndrome: a national experience

18. Ionizing radiation induces long-term senescence in endothelial cells through mitochondrial respiratory complex II dysfunction and superoxide generation

19. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies

20. Sensing of cell stress by human γδ TCR-dependent recognition of annexin A2

21. Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease

22. CD21 deficiency in two siblings with recurrent respiratory infections and hypogammaglobulinemia

23. TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress

24. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study

25. Sequencing of the hypoxia pathway genes in patients with congenital erythrocytoses by next generation sequencing

26. Torrefaction and pyrolysis of metal-enriched poplars from phytotechnologies: Effect of temperature and biomass chlorine content on metal distribution in end-products and valorization options

27. Gene panel sequencing in idiopathic erythrocytosis

28. Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study

29. A driver role for GABA metabolism in controlling stem and proliferative cell state through GHB production in glioma

30. Proportions of blood-borne Vd1þ and Vd2þ T-cells are associated with overall survival of melanoma patients treated with ipilimumab

31. Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia

32. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study

33. The E3 ubiquitin ligase MARCH3 controls the endothelial barrier

34. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients

35. Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients

36. Radioimmunotherapy: From Current Clinical Success to Future Industrial Breakthrough?

37. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study

38. Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma

39. ImmunoPET to help stratify patients for targeted therapies and to improve drug development

40. Luteolin Impacts on the DNA Damage Pathway in Oral Squamous Cell Carcinoma

41. Ionic liquid supported organotin reagents to prepare molecular imaging and therapy agents †

42. Long-Term Toxicity of 213Bi-Labelled BSA in Mice

43. Atteinte ganglionnaire sentinelle et cancer de la prostate : quel impact sur la survie sans recidive ? À propos de 200 patients

44. IRES-dependent translation of the long non coding RNA meloe in melanoma cells produces the most immunogenic MELOE antigens

45. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

46. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency)

47. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire

48. Mechanisms of action of antithymocyte globulin: old dogs with new tricks!

49. Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab

50. The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer

Catalog

Books, media, physical & digital resources